GPCR News 

July 2022 Confo Therapeutics receives €1.7 million VLAIO grant for further research on GPCR modulators for rare diseases "29/06/2022...

June 2022 "G protein-coupled receptors (GPCRs) represent a major therapeutic target class as they play a key role in many (patho-)...

March 2022 Confo Therapeutics Doses First Subjects In Phase 1 Clinical Trial Of CFTX-1554 For The Treatment Of Neuropathic Pain "—...

December 2021 "30/11/2021 Confo will work together with Regeneron to apply its GPCR drug discovery platform to enable functional antibody...